30 closest matches · ranked by relevance
Dyslipidemias · Hypercholesterolemia · Hypertriglyceridemia
Primary: Total Cholesterol (TC) Levels at First Acute Coronary Event — 163.5 mg/dL
Dyslipidemia
Primary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 — -31.19; -33.83; -41.09; -46.62 Percent Change (%) — p=< 0.001
Dyslipidemias · Cardiovascular Diseases · Hypertriglyceridemia
Primary: Percentage of Triglyceride (TG) Change — -38.12 percentage of TG change
Hyperlipidemia, Periodontitis, Gingivitis
Primary: Gingival Crevicular Fluid Level of Malondialdehyde (MDA) as a Marker of Lipid Oxidation. — 144.09; 298.52; 802.09; 139.50 pg/ml
Dyslipidaemia
Primary: Change in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12. — 0.978; 0.206; 0.270; 0.606 Ratio
Dyslipidemias · Lipid Metabolism Disorders · Metabolic Diseases
Primary: Percent Change From Baseline for Apolipoprotein B (ApoB) at Day 180 — -11.6; -14.1; -24.3; -19.0 Percent change — p=0.691
Atherogenic Dyslipidemia · Obesity Associated Disorder
Primary: Changes Serum Triglyceride Levels — 223.1; 241.2; 227.0; 267.2 mg/dl — p=0.0001
Cardiovascular Diseases · Heart Diseases · HIV Infections
Primary: Triglycerides — 199; 216.9; 155.1; 177.6 mg/dL
Dyslipidemia · Cardiovascular Diseases · Hypercholesterolemia
Primary: Mean Low Density Lipid-Cholesterol (LDL-C) Levels in High and Very High Risk Cardiovascular Participants — 2.40; 1.99 mmol/L
Atherosclerosis
Primary: Change From Baseline to Week 4 in Plasma Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity — 0.961; 0.494; 0.404; 0.313 Log(millimole per milliliter per minute)…
Dyslipidemia
Primary: Percent Changes From Baseline to End-of-treatment in Non-HDL Cholesterol, HDL Cholesterol, and Triglycerides by LCP-AtorFen Versus Atorvastatin Monotherapy — -44.8…
Dyslipidaemias · Dyslipidemias
Primary: The GSK256073 Area Under Concentration-time Curve (AUC) and High Density Lipoprotein Cholesterol (HDLc) Data to Evolve the Exposure-response…
Hyperlipidaemia
Primary: Percentage Change From Baseline on Serum LDL-C — -56.7; 5.6 percent change — p=<0.001
Type 2 Diabetes Mellitus
Primary: Mean ApoB Concentration Before and After Evolocumab — 75.9; 35.3 mg/dL — p=<0.001
Diabetic Retinopathy · Dyslipidemia
Primary: Increase in Acid Sphingomyelinase (ASM) Expression and Activity in Bone Marrow-derived Endothelial Progenitor Cells (EPCs) — 0.2; 0.5 nM/hr
Mixed Dyslipidemia
Primary: Triglycerides After 90 Days — 2.3; 1.1; 1.3 mmol/L
Hypercholesterolemia With Concomitant Type 2 Diabetes
Primary: Percent Change in Non-high-density Lipoprotein Cholesterol (HDL-C) Level — -31.3; -32.8 Percent change
Dyslipidemia
Primary: Percentage of Participants Achieving Target Lipid Values — 46.8 Percentage of participants
Metabolic Syndrome
Primary: Basal HDL-cholesterol Level — 39.5 mg/dL
Dyslipidemia
Primary: Total Cholesterol Before and After Simvastatin/Ezetimibe Administration — 255; 253; 180; 215 mg/dl — p=<0.05
Cardiovascular Diseases · Coronary Artery Disease
Primary: Percentage of Participants Achieving LDL Level Less Than or Equal to (≤) 100 mg/dL at the 6 Month Visit — 51.52 percentage of participants
Dyslipidemias
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration Part A and Part B — 0…
Dyslipidemia
Primary: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) (mg/dL) — -0.3; -1.5 Percent Change — p=0.926
Dyslipidemia
Primary: Percent Change From Baseline in Non-HDL-C at Week 24: Overall Intent-to-treat (ITT) Analysis — -37.3; -4.7 Percent change — p=<0.0001
Dyslipidemia
Primary: Change in Non-HDL Cholesterol, HDL Cholesterol, TG Levels From Baseline to End of Treatment — -48.2; -43.6; -42.0; 2.6 percent change
Primary Hypercholesterolemia · Mixed Dyslipidemia
Primary: Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12 — -10.0; -5.5 Percent — p=0.006
Primary Hypercholesterolemia · Mixed Dyslipidemia
Primary: Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) — -44.6; -46.9; -48.9; -50.4 Percentage Change
Dyslipidemia
Primary: Percent Change From Baseline to 12 Weeks Endpoint in High Density Lipoprotein Cholesterol (HDL-C) With LY2484595 in Combination With Atorvastatin and Atorvastatin…
Hyperlipidemia
Primary: LDL Level Change From Baseline — -63.4; -54.6 mg/dl — p=0.391
Hyperlipoproteinemia Type I · Hypertriglyceridemia
Primary: Fasting Serum Triglycerides — 705; 1827; 1511; 1007 mg/dL